Advarra Acquires YourEncore
Advarra has announced the acquisition of YourEncore.
“We’re excited that YourEncore is becoming part of Advarra,” said Gadi Saarony, CEO of Advarra. Together, they will aim to progress a shared vision of accelerating the drug development lifecycle and the delivery of therapies to patients.
Advarra’s consulting services currently assist biopharmaceutical companies, device manufacturers, academic medical centers, health systems, and institutions in nearly 60 countries. “The addition of YourEncore is a huge step forward for Advarra’s consulting services business, building on and broadening our existing team and solutions across the clinical research spectrum,” said Scott Uebele, President and Chief Research Services Officer of Advarra.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
